Dr. Daniel Sipple
Chief Medical Officer
Dr. Daniel Sipple is board certified in physical medicine and rehabilitation with sub-specialty board certification in pain medicine. He trained at the Rehabilitation Institute of Chicago, now the Shirley Ryan Ability Lab, the #1 rated rehabilitation hospital in US News and World Report over 20 years running. He served on faculty at Northwestern University Medical School while working at RIC’s American Academy of Pain Medicine Center of Excellence. He subsequently practiced in Denver Colorado for two years, working along side former team physicians of the Denver Broncos and Colorado Rockies. Thereafter, at the Mayo Clinic in Eau Claire, Wisconsin via the Pain Clinic of NW Wisconsin. He served at the medical director the Health East Spine Center, and service line medical director over Neurosurgery, Behavioral Health, Pain and Spine for the health system. He worked at Midwest Spine and Brian Institute for seven years before founding Sipple Medical Innovations. Dr. Sipple is the co-founder of InSitu Biologics, and co-inventor of INSB 200, sustained release non- opiate pain killer for post operative pain set to enter phase I FDA clinical trials in 2024. The drug was developed to reduce pre, peri and post operative use of opioids as well as to reduce cost, as pain is a rate limiting step in performing outpatient surgeries in low cost ambulatory surgery centers. Medicare saved $34 Billion pre-covid with the use of Exparel, a sustained release local anesthetic. INSB 200 is second to the space, with 5x the payload, 2x the duration being 30% less cardiotoxic. InSitu Biologics is partnered with the Mayo Clinic. The drug delivery platform co-patented by Dr. Sipple is co-developed with Mayo Clinic to deliver monoclonal anti-bodies for cancer therapy. This is designed to reduce systemic effects of chemotherapy and radiation and deliver a higher payload to target ratio safely to tumors.
The platform’s application for sustained release medication has a long runway for numerous therapeutics. Dr. Sipple is the patient holder in safe needle technology and the founder of Acies Medical, makers of the Acies Smart Needle. The Acies Smart Needle is the only medical device specifically invented to prevent the Medicare defined Never Event of Inadvertent Embolism. Such events are linked to myocarditis, vaccine hesitancy- a top 10 global public health concern, and Long Covid, a $3.7 Trillion global economic and humanistic burden. Acies Smart Needle is designed to eliminate inadvertent vaccine embolism, change the narrative on vaccines, and save a generation from life long complications of long Covid, much as the Sabin and Salk Vaccines did for Poliio. Needles are 175 years old and ripe for disruption. The Never Event of inadvertent embolism is linked to stroke and blindness with facial filler use, and death via pulmonary embolism in Brazilian Butt lifts. Safe and effective IV access is critical to equitable health care, and consistent with United Nations Sustainable Development Goals, as life and death, particularly in developing countries, can hinge upon rapid, safe and accurate use. Dr. Sipple formerly served on the Board of Directors for the Society for Brain Mapping and Therapeutics (SBMT), a NASA Spinout, and part of President Obama’s BRAIN Initiative. In that capacity has presented to the United States Congress, the California Legislature, the White House, along with world leaders at the Neuroscience 20 Summit in conjunction with the G20 in Buenos Aires, Argentina, Osaka Japan and New Delhi India. Dr. Sipple contributed to SBMT’s lobbying efforts to create neurotech parks across the US. $500 Million was funded by President Biden and the US Department of Commerce to launch 31 tech parks a oss the country to accelerate development in technology, including neurotech.
In the entrepreneurial space, Dr. Sipple is a co-founder of Hypercharge Clinics, based in Minnesota. The goal of Hypercharge is to bring emerging treatments including photobiomodulation to the public at low cost at large scale, largely for musculoskeletal and wellness applications, where it’s use is FDA cleared. Early randomized controlled trials of PBM have arrested and reversed dementia in 2 month in 10 minutes of treatment twice daily. Dementia alone will consume Medicare’s budget in it’s entirety by 2050. Similarly for Long Covid Brain fog, PBM has demonstrated strong resolution of symptoms in 12 sessions over one month. Dr Sipple serves on the board of Directors of Kinuu, makers of Brainy Act, gamified occupational therapy for Autism, Aspberger’s, ADHD, and dyslexia. Early data demonstrated 22-26% improvement over 6 domains after 60 sessions of therapy. The average Autism clinic has a 1 year waiting period and earns over $10 Million. Gamified therapy is drug free, low cost and reduces caregiver burden. He also serves on the board of directors of Thera-Clean, and emerging technology with drug free applications for wound care. Dr. Sipple’s learned inventing from his father, Ralph Edward Sipple, a farm raised engineer, and holder of 18 patents, including video on demand.
Dr. Daniel Sipple
Chief Medical Officer
Dr. Daniel Sipple is board certified in physical medicine and rehabilitation with sub-specialty board certification in pain medicine. He trained at the Rehabilitation Institute of Chicago, now the Shirley Ryan Ability Lab, the #1 rated rehabilitation hospital in US News and World Report over 20 years running. He served on faculty at Northwestern University Medical School while working at RIC’s American Academy of Pain Medicine Center of Excellence. He subsequently practiced in Denver Colorado for two years, working along side former team physicians of the Denver Broncos and Colorado Rockies. Thereafter, at the Mayo Clinic in Eau Claire, Wisconsin via the Pain Clinic of NW Wisconsin. He served at the medical director the Health East Spine Center, and service line medical director over Neurosurgery, Behavioral Health, Pain and Spine for the health system. He worked at Midwest Spine and Brian Institute for seven years before founding Sipple Medical Innovations. Dr. Sipple is the co-founder of InSitu Biologics, and co-inventor of INSB 200, sustained release non- opiate pain killer for post operative pain set to enter phase I FDA clinical trials in 2024. The drug was developed to reduce pre, peri and post operative use of opioids as well as to reduce cost, as pain is a rate limiting step in performing outpatient surgeries in low cost ambulatory surgery centers. Medicare saved $34 Billion pre-covid with the use of Exparel, a sustained release local anesthetic. INSB 200 is second to the space, with 5x the payload, 2x the duration being 30% less cardiotoxic. InSitu Biologics is partnered with the Mayo Clinic. The drug delivery platform co-patented by Dr. Sipple is co-developed with Mayo Clinic to deliver monoclonal anti-bodies for cancer therapy. This is designed to reduce systemic effects of chemotherapy and radiation and deliver a higher payload to target ratio safely to tumors.
The platform’s application for sustained release medication has a long runway for numerous
therapeutics.Dr. Sipple is the patient holder in safe needle technology and the founder of Acies Medical, makers of
the Acies Smart Needle. The Acies Smart Needle is the only medical device specifically invented to prevent the Medicare defined Never Event of Inadvertent Embolism. Such events are linked to myocarditis, vaccine hesitancy- a top 10 global public health concern, and Long Covid, a $3.7 Trillion global economic and humanistic burden. Acies Smart Needle is designed to eliminate inadvertent vaccine embolism, change the narrative on vaccines, and save a generation from life long complications of long Covid, much as the Sabin and Salk Vaccines did for Poliio. Needles are 175 years old and ripe for disruption. The Never Event of inadvertent embolism is linked to stroke and blindness with facial filler use, and death via pulmonary embolism in Brazilian Butt lifts. Safe and effective IV access is critical to equitable health care, and consistent with United Nations Sustainable Development Goals, as life and death, particularly in developing countries, can hinge upon rapid, safe and accurate use. Dr. Sipple formerly served on the Board of Directors for the Society for Brain Mapping and Therapeutics (SBMT), a NASA Spinout, and part of President Obama’s BRAIN Initiative. In that capacity has presented to the United States Congress, the California Legislature, the White House, along with world leaders at the Neuroscience 20 Summit in conjunction with the G20 in Buenos Aires, Argentina, Osaka Japan and New Delhi India. Dr. Sipple contributed to SBMT’s lobbying efforts to create neurotech parks across the US. $500 Million was funded by President Biden and the US Department of Commerce to launch 31 tech parks a oss the country to accelerate development in technology, including neurotech.
In the entrepreneurial space, Dr. Sipple is a co-founder of Hypercharge Clinics, based in Minnesota. The goal of Hypercharge is to bring emerging treatments including photobiomodulation to the public at low cost at large scale, largely for musculoskeletal and wellness applications, where it’s use is FDA cleared. Early randomized controlled trials of PBM have arrested and reversed dementia in 2 month in 10 minutes of treatment twice daily. Dementia alone will consume Medicare’s budget in it’s entirety by 2050. Similarly for Long Covid Brain fog, PBM has demonstrated strong resolution of symptoms in 12 sessions over one month. Dr Sipple serves on the board of Directors of Kinuu, makers of Brainy Act, gamified occupational therapy for Autism, Aspberger’s, ADHD, and dyslexia. Early data demonstrated 22-26% improvement over 6 domains after 60 sessions of therapy. The average Autism clinic has a 1 year waiting period and earns over $10 Million. Gamified therapy is drug free, low cost and reduces caregiver burden. He also serves on the board of directors of Thera-Clean, and emerging technology with drug free applications for wound care. Dr. Sipple’s learned inventing from his father, Ralph Edward Sipple, a farm raised engineer, and holder of 18 patents, including video on demand.